Estrella Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-8.85	-7.31	-11.11	-1.69	-0.73
Stock-Based Compensation	0.86	1.19	0.41	0.13	0.06
Change in Accounts Payable	0.01	-9.33	8.39	-	-
Change in Other Net Operating Assets	1.84	-0.62	0.98	0.11	-
Operating Cash Flow	-6.23	-16.07	-1.34	-1.44	-0.67
Other Investing Activities	-	4.96	-0.27	-	-
Investing Cash Flow	-	4.96	-0.27	-	-
Short-Term Debt Issued	-	0.3	-	-	-
Total Debt Issued	-	0.3	-	-	-
Short-Term Debt Repaid	-	-0.3	-	-	-
Total Debt Repaid	-	-0.3	-	-	-
Issuance of Common Stock	0.16	10	-	0.02	-
Repurchase of Common Stock	-0.43	-5.43	-	-	-
Other Financing Activities	-	-0.8	-	0.52	0.67
Financing Cash Flow	-0.27	12.79	-	5.53	0.67
Net Cash Flow	-6.5	1.69	-1.61	4.09	-
Cash Interest Paid	-	0	-	-	-
Cash Income Tax Paid	-	0	-	-	-
Levered Free Cash Flow	-	-12.95	2.81	-	-
Unlevered Free Cash Flow	-	-12.95	2.81	-	-
Change in Net Working Capital	-	9.58	-9.35	-	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q